Company

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals develops treatments for rare genetic diseases affecting weight regulation.

About

Founded in 2008 and based in Massachusetts, US, Rhythm Pharmaceuticals develops treatments for rare genetic diseases associated with chronic weight management in adults and children aged six and older. The FDA approved IMCIVREE (setmelanotide) in November 2020. In March 2024, the company raised USD 150 million in PIPE funding led by Perceptive Advisors. It listed on Nasdaq in October 2017 under RYTM.

8Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in